These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 31175631)

  • 1. Biosimilars: A Value Proposition.
    de Mora F
    BioDrugs; 2019 Aug; 33(4):353-356. PubMed ID: 31175631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.
    Kabir ER; Moreino SS; Sharif Siam MK
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M; Yoon W; McKay J
    Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
    Chen BK; Yang YT; Bennett CL
    Drugs; 2018 Nov; 78(17):1777-1781. PubMed ID: 30446980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A health economic guide to market access of biosimilars.
    Simoens S; Vulto AG
    Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
    [No Abstract]   [Full Text] [Related]  

  • 8. Short and long-term economic implications of biosimilars.
    Al Meslamani AZ
    Expert Opin Biol Ther; 2024 Jul; 24(7):567-570. PubMed ID: 38231118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current market and regulatory landscape of biosimilars.
    Bhatt V
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status of Biosimilars in Oncology.
    Camacho LH
    Drugs; 2017 Jun; 77(9):985-997. PubMed ID: 28477160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: Here and Now.
    Lemery SJ; Esteva FJ; Weise M
    Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
    Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
    J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report.
    Barcina Lacosta T; Inotai A; Pereira CL; Barbier L; Simoens S
    Value Health; 2024 May; 27(5):543-551. PubMed ID: 38702140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evidence supporting the marketing authorization of biosimilars in Europe.
    Allocati E; Bertele' V; Gerardi C; Garattini S; Banzi R
    Eur J Clin Pharmacol; 2020 Apr; 76(4):557-566. PubMed ID: 31897530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.